Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, toxicity, dosing, and antiviral effects
of epigallocatechin gallate (EGCG) in capsule form (Polyphenon® E), administered orally twice
daily at three different doses in HIV-1-infected clinically stable, treatment-naïve and
treatment-experienced adults not on concomitant antiretroviral (ARV) therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Baylor College of Medicine
Collaborator:
National Center for Complementary and Integrative Health (NCCIH)